Acurx Advances Ibezapolstat with PATHFINDER Trial Enrollment
Event summary
- First patient enrolled in PATHFINDER Phase 2 trial for ibezapolstat in multiply-recurrent C. difficile infection (rCDI).
- PATHFINDER trial aims to support a U.S. NDA filing based on a single Phase 3 trial.
- ASPIRE Phase 3 trial planned for non-inferiority design comparing ibezapolstat to vancomycin.
- FDA open to discussing NDA submission with only a single Phase 3 trial, depending on clinical data.
- Ibezapolstat designed to maintain healthy gut microbiome, potentially reducing recurrence.
The big picture
Acurx Pharmaceuticals is advancing its lead antibiotic candidate, ibezapolstat, through critical clinical trials aimed at treating and preventing recurrent C. difficile infections. The company's strategic focus on a Gram-positive selective spectrum (GPSS®) antibiotic could shift the paradigm from using two agents to one for both treatment and prevention. The PATHFINDER and ASPIRE trials are pivotal in determining the regulatory pathway and potential market approval for ibezapolstat, addressing a significant unmet medical need in infectious disease management.
What we're watching
- Regulatory Pathway
- Whether the FDA will ultimately accept a single Phase 3 trial for NDA submission, given the totality of clinical data.
- Clinical Efficacy
- The pace at which PATHFINDER and ASPIRE trials progress and whether they demonstrate robust efficacy and safety data.
- Funding Availability
- How Acurx secures sufficient resources to fund the ASPIRE Phase 3 trial, which is contingent on public or private partnerships.